How to buy Aura Biosciences stock (AURA)

Aura Biosciences is a biotechnology business based in the US. Aura Biosciences shares (AURA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $8.33 – an increase of 1.59% over the previous week. Aura Biosciences employs 88 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Aura Biosciences stock

Buy Aura Biosciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aura Biosciences stock price (NASDAQ: AURA)

Use our graph to track the performance of AURA stocks over time.

Aura Biosciences shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$8.33
52-week range	$6.63 - $12.38
50-day moving average more info button	$9.65
200-day moving average more info button	$8.40
Wall St. target price	$21.83
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.73

Is it a good time to buy Aura Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aura Biosciences price performance over time

Historical closes compared with the close of $8.41 from 2024-12-26

1 week (2024-12-20)	2.56%
1 month (2024-11-27)	-6.56%
3 months (2024-09-27)	-6.87%
6 months (2024-06-27)	15.52%

1 year (2023-12-27)	-7.48%
2 years (2022-12-27)	-19.83%
3 years (2021-12-27)	17.61
5 years (2019-12-24)	N/A

Aura Biosciences financials

Gross profit TTM	$0
Return on assets TTM	-30.22%
Return on equity TTM	-50.99%
Profit margin	0%
Book value	$3.51
Market Capitalization more info button	$411.1 million

TTM: trailing 12 months

Aura Biosciences share dividends

We're not expecting Aura Biosciences to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)

Aura Biosciences share price volatility

Over the last 12 months, Aura Biosciences's shares have ranged in value from as little as $6.63 up to $12.3782. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aura Biosciences's is 0.332. This would suggest that Aura Biosciences's shares are less volatile than average (for this exchange).

To put Aura Biosciences's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.615
• Moderna (MRNA.US): 1.69
• Johnson-and-Johnson (JNJ.US): 0.518

Aura Biosciences overview

Aura Biosciences, Inc. , a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Frequently asked questions

null
What percentage of Aura Biosciences is owned by insiders or institutions?
Currently 5.08% of Aura Biosciences shares are held by insiders and 77.548% by institutions. How many people work for Aura Biosciences?
Latest data suggests 88 work at Aura Biosciences. When does the fiscal year end for Aura Biosciences?
Aura Biosciences's fiscal year ends in December. Where is Aura Biosciences based?
Aura Biosciences's address is: 80 Guest Street, Boston, MA, United States, 02135 What is Aura Biosciences's ISIN number?
Aura Biosciences's international securities identification number is: US05153U1079